Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Follow-Up Questions
¿Cuál es el ratio P/E de Collegium Pharmaceutical Inc (COLL)?
El ratio P/E de Collegium Pharmaceutical Inc es 16.2769
¿Quién es el CEO de Collegium Pharmaceutical Inc?
Mr. Vikram Karnani es el President de Collegium Pharmaceutical Inc, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción COLL?
El precio actual de COLL es de $33.74, ha decreased un 0.58% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Collegium Pharmaceutical Inc?
Collegium Pharmaceutical Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Collegium Pharmaceutical Inc?
La capitalización bursátil actual de Collegium Pharmaceutical Inc es $1.0B
¿Es Collegium Pharmaceutical Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 7 analistas han realizado calificaciones de análisis para Collegium Pharmaceutical Inc, incluyendo 3 fuerte compra, 6 compra, 2 mantener, 0 venta, y 3 fuerte venta